ProCE Banner Series

Precision Therapeutics for NF1-Associated Tumors: Improved Outcomes Through Targeted MEK Inhibition

Join us either in person or online for this CME/CE -certified satellite symposium held in conjunction with the Society for Neuro-Oncology (SNO) Annual Meeting in Houston, Texas, featuring expert perspectives on MEK inhibition for the treatment of NF1-associated tumors. Bring your questions for the live Q&A session with the expert panel faculty at the end of the session.

The Society for Neuro-Oncology has reviewed and approved this symposium as appropriate for presentation as an Independent Supported Symposium. The symposium constitutes the content and views of the sponsor and is not part of the official SNO Annual Meeting program.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended for medical oncologists, neurologists, neuro-oncologists, pediatric neuro-oncologists, nurses, physician associates, pharmacists, and other healthcare professionals who care for patients with NF1-associated tumors.

All Events

Precision Therapeutics for NF1-Associated Tumors: Improved Outcomes Through Targeted MEK Inhibition

Upcoming Events

November

23

2024

12:45 PM - 1:45 PM Central Time (CT)

In-personVirtual

George R. Brown Convention Center, 1001 Avenida de las Americas, Houston, Texas 77010

Faculty

ProCE Banner Faculty
Jaishri Blakeley, MD

The Marjorie Bloomberg Tiven Professor of Neurofibromatosis
Director, The Neurofibromatosis Therapeutic Acceleration Program
Director, The Johns Hopkins Comprehensive Neurofibromatosis Program
Department of Neurology, Neruo-Oncology
The Johns Hopkins School of Medicine
Baltimore, Maryland

ProCE Banner Faculty
Michael J. Fisher, MD

Chief, Neuro-Oncology Section
Director, Neurofibromatosis Program
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology  
Professor of Pediatrics
Division of Oncology
The Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Topics

Sarcomas

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Neurofibromatosis.

Target Audience
This educational program is intended for medical oncologists, neurologists, neuro-oncologists, pediatric neuro-oncologists, nurses, physician associates, pharmacists, and other healthcare professionals who care for patients with NF1-associated tumors.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Evaluate the genetic mutations and molecular pathways involved in the development of NF1-associated tumors and their implications for targeted therapy
  • Incorporate MEK inhibitors into treatment plans for patients with NF1-associated plexiform neurofibromas based on the latest evidence, recommendations, and individual patient and tumor characteristics
  • Formulate supportive care strategies for the long-term management of patients with NF1, considering the chronic nature of the disease, toxicity management, surveillance for malignant transformation, and quality of life issues
  • Evaluate available clinical evidence and potential expanded indications for emerging targeted agents in NF1 to prepare for efficient integration of emerging therapies into clinical practice

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-222-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.